Comparative efficacy and safety of antidiabetic drugs for obese patients with knee osteoarthritis: a network meta-analysis of randomized controlled trials
Abstract
BACKGROUND: Obesity-related knee osteoarthritis (KOA) is a significant public health concern, affecting quality of life. Recent evidence suggests some antidiabetic drugs may help manage KOA in obese patients due to their anti-inflammatory and weight-reducing effects.
OBJECTIVE: This study aimed to compare the efficacy and safety of antidiabetic drugs for managing pain and adverse events in obese KOA patients through a network meta-analysis of randomized controlled trials (RCTs).
METHODS: A systematic search of multiple databases identified relevant RCTs on antidiabetic drugs for KOA. Treatment efficacy was assessed using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score improvement, and safety was evaluated based on the incidence of serious adverse events. The Surface Under the Cumulative Ranking Curve (SUCRA) scores were used to rank the treatments, and effect sizes were reported as mean differences (MD) with 95% confidence intervals (CI).
RESULTS: A total of nine RCTs were included in the analysis. For pain relief, metformin demonstrated the largest effect size with a mean difference of - 1.13 (95% CI - 1.48, - 0.78) compared to usual care, followed by Metformin-Phosphatidylcholine (MFPH) (- 0.92, 95% CI - 1.70, - 0.13) and semaglutide (- 0.90, 95% CI - 1.48, - 0.32). In terms of safety, usual care exhibited the lowest risk of adverse events, with liraglutide (0.09, 95% CI - 0.74, 0.92) and semaglutide (0.21, 95% CI - 0.46, 0.88) also…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.